These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1097 related articles for article (PubMed ID: 18782303)
21. The independent impact of extended pattern biopsy on prostate cancer stage migration. Master VA; Chi T; Simko JP; Weinberg V; Carroll PR J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288 [TBL] [Abstract][Full Text] [Related]
22. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441 [TBL] [Abstract][Full Text] [Related]
23. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? Makarov DV; Sanderson H; Partin AW; Epstein JI J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053 [TBL] [Abstract][Full Text] [Related]
24. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796 [TBL] [Abstract][Full Text] [Related]
25. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695 [TBL] [Abstract][Full Text] [Related]
26. Prostate cancer volume at biopsy predicts clinically significant upgrading. Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180 [TBL] [Abstract][Full Text] [Related]
27. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486 [TBL] [Abstract][Full Text] [Related]
28. Should we replace the Gleason score with the amount of high-grade prostate cancer? Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer. Ahyai SA; Zacharias M; Isbarn H; Steuber T; Eichelberg C; Köllermann J; Fisch M; Karakiewicz PI; Huland H; Graefen M; Chun FK BJU Int; 2010 Aug; 106(4):478-83. PubMed ID: 20128781 [TBL] [Abstract][Full Text] [Related]
30. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? Boorjian SA; Bianco FJ; Scardino PT; Eastham JA BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197 [TBL] [Abstract][Full Text] [Related]
31. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. Moussa AS; Kattan MW; Berglund R; Yu C; Fareed K; Jones JS BJU Int; 2010 Feb; 105(3):352-8. PubMed ID: 19681898 [TBL] [Abstract][Full Text] [Related]
32. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673 [TBL] [Abstract][Full Text] [Related]
33. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725 [TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776 [TBL] [Abstract][Full Text] [Related]
36. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Poulos CK; Daggy JK; Cheng L Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065 [TBL] [Abstract][Full Text] [Related]
37. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy. Sankin A; Tareen B; Lepor H Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170 [TBL] [Abstract][Full Text] [Related]
38. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ; J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131 [TBL] [Abstract][Full Text] [Related]
39. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951 [TBL] [Abstract][Full Text] [Related]
40. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Miyake H; Kurahashi T; Takenaka A; Hara I; Fujisawa M Urol Int; 2007; 79(4):302-6. PubMed ID: 18025846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]